Evidence map›Paper›PMID 28274246›Full record

Trial reportCritical care (London, England)2017

Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome.

Nikolaos Antonakos, Thomas Tsaganos, Volker Oberle, Iraklis Tsangaris, Malvina Lada, Aikaterini Pistiki, Nikolaos Machairas, Maria Souli, Michael Bauer, Evangelos J Giamarellos-Bourboulis

2 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Critical care (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01223690 phase3completednot on this map

A Double-blind Randomized Placebo-controlled Clinical Trial of the Safety and Efficacy of Intravenous Clarithromycin as Immunomodulatory Therapy for the Management of Sepsis

TypeinterventionalSponsorUniversity of AthensRan2007 to 2011Enrolled600ConditionsSepsis, Severe Sepsis, Septic ShockArmsClarithromycin, Dextrose 5%
NCT03841162 completednot on this mapstarted 2019, after this paper: background citation

Fast Assay for Pathogen Identification and Characterization - Prospective Observational Study

TypeobservationalSponsorHasselt UniversityRan2019 to 2020Enrolled1,957ConditionsBacteremia, Sepsis, Septic Shock
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Increases in inflammatory and CD14Critical care (London, England) · 2018
    Observational
  17. Article
  18. Observational
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Nikolaos Antonakos4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Thomas Tsaganos4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Volker OberleDepartment of Clinical Chemistry and Laboratory Medicine, Jena University Hospital, Jena, Germany.
Iraklis Tsangaris2nd Department of Critical Care Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Malvina Lada2nd Department of Internal Medicine, Sismanogleion Athens General Hospital, Athens, Greece.
Aikaterini Pistiki4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Nikolaos Machairas4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Maria Souli4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Michael BauerCentre for Sepsis Control and Care, Jena University Hospital, Jena, Germany.
Evangelos J Giamarellos-Bourboulis4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece. egiamarel@med.uoa.gr.
National and Kapodistrian University of Athens · GRJena University Hospital · DESismanoglio General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFailure of circulating monocytes for adequate cytokine production is a trait of sepsis-induced immunosuppression; however, its duration and association with final outcome are poorly understood.

methodsWe conducted a substudy of a large randomised clinical trial. Peripheral blood mononuclear cells (PBMCs) were isolated within the first 24 h from the onset of systemic inflammatory response syndrome in 95 patients with microbiologically confirmed or clinically suspected gram-negative infections. Isolation was repeated on days 3, 7 and 10. PBMCs were stimulated for cytokine production. The study endpoints were the differences between survivors and non-survivors, the persistence of immunosuppression, and determination of admission clinical signs that can lead to early identification of the likelihood of immunosuppression.

resultsPBMCs of survivors produced significantly greater concentrations of tumour necrosis factor-α (TNF-α), interleukin (IL)-6, IL-8, IL-10, interferon-γ and granulocyte-macrophage colony-stimulating factor after day 3. Using ROC analysis, we found that TNF-α production less than 250 pg/ml after lipopolysaccharide stimulation on day 3 could discriminate patients from healthy control subjects; this was associated with a 5.18 OR of having an unfavourable outcome (p = 0.046). This trait persisted as long as day 10. Logistic regression analysis showed that cardiovascular failure on admission was the only independent predictor of defective TNF-α production on day 3.

conclusionsDefective TNF-α production is a major trait of sepsis-induced immunosuppression. It is associated with significant risk for unfavourable outcome and persists until day 10. Cardiovascular failure on admission is predictive of defective TNF-α production during follow-up.

trial registrationClinicalTrials.gov identifier: NCT01223690 . Registered on 18 October 2010.

Indexed as

AgedAged, 80 and overClarithromycinDecision Support TechniquesFemaleGram-Negative BacteriaGranulocyte-Macrophage Colony-Stimulating FactorGreeceHumansInfectionsInterferon-gammaInterleukin-10Interleukin-6Interleukin-8Leukocytes, MononuclearLogistic ModelsClarithromycinGranulocyte-Macrophage Colony-Stimulating Factorgranulocyte-macrophage colony-stimulating factor, Arg(21)-IL10 protein, humanIL6 protein, humanInterferon-gammaInterleukin-10Interleukin-6Interleukin-8PlacebosRecombinant ProteinsTNF protein, humanTumor Necrosis Factor-alphaImmunosuppressionPredictionSepsisSurvival

Identifiers

PMID28274246
PMCPMC5343541
OpenAlexW2592495968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.